Literature DB >> 18281481

Use of a cryptic splice site for the expression of huntingtin interacting protein 1 in select normal and neoplastic tissues.

Chiron W Graves1, Steven T Philips, Sarah V Bradley, Katherine I Oravecz-Wilson, Lina Li, Alice Gauvin, Theodora S Ross.   

Abstract

Huntingtin interacting protein 1 (HIP1) is a 116-kDa endocytic protein, which is necessary for the maintenance of several tissues in vivo as its deficiency leads to degenerative adult phenotypes. HIP1 deficiency also inhibits prostate tumor progression in mice. To better understand how deficiency of HIP1 leads to such phenotypes, we analyzed tumorigenic potential in mice homozygous for a Hip1 mutant allele, designated Hip1(Delta 3-5), which is predicted to result in a frame-shifted, nonsense mutation in the NH(2) terminus of HIP1. In contrast to our previous studies using the Hip1 null allele, an inhibition of tumorigenesis was not observed as a result of the homozygosity of the nonsense Delta 3-5 allele. To further examine the contrasting results from the prior Hip1 mutant mice, we cultured tumor cells from homozygous Delta 3-5 allele-bearing mice and discovered the presence of a 110-kDa form of HIP1 in tumor cells. Upon sequencing of Hip1 DNA and message from these tumors, we determined that this 110-kDa form of HIP1 is the product of splicing of a cryptic U12-type AT-AC intron. This event results in the insertion of an AG dinucleotide between exons 2 and 6 and restoration of the reading frame. Remarkably, this mutant protein retains its capacity to bind lipids, clathrin, AP2, and epidermal growth factor receptor providing a possible explanation for why tumorigenesis was not altered after this knockout mutation. Our data show how knowledge of the transcript that is produced by a knockout allele can lead to discovery of novel types of molecular compensation at the level of splicing.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18281481      PMCID: PMC3135020          DOI: 10.1158/0008-5472.CAN-07-5892

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  30 in total

1.  The huntingtin interacting protein HIP1 is a clathrin and alpha-adaptin-binding protein involved in receptor-mediated endocytosis.

Authors:  S Waelter; E Scherzinger; R Hasenbank; E Nordhoff; R Lurz; H Goehler; C Gauss; K Sathasivam; G P Bates; H Lehrach; E E Wanker
Journal:  Hum Mol Genet       Date:  2001-08-15       Impact factor: 6.150

2.  HIP1 and HIP12 display differential binding to F-actin, AP2, and clathrin. Identification of a novel interaction with clathrin light chain.

Authors:  Valerie Legendre-Guillemin; Martina Metzler; Martine Charbonneau; Lu Gan; Vikramjit Chopra; Jacynthe Philie; Michael R Hayden; Peter S McPherson
Journal:  J Biol Chem       Date:  2002-03-11       Impact factor: 5.157

3.  Clathrin- and AP-2-binding sites in HIP1 uncover a general assembly role for endocytic accessory proteins.

Authors:  S K Mishra; N R Agostinelli; T J Brett; I Mizukami; T S Ross; L M Traub
Journal:  J Biol Chem       Date:  2001-09-27       Impact factor: 5.157

4.  HIP1 functions in clathrin-mediated endocytosis through binding to clathrin and adaptor protein 2.

Authors:  M Metzler; V Legendre-Guillemin; L Gan; V Chopra; A Kwok; P S McPherson; M R Hayden
Journal:  J Biol Chem       Date:  2001-08-21       Impact factor: 5.157

5.  Huntingtin interacting protein 1 Is a clathrin coat binding protein required for differentiation of late spermatogenic progenitors.

Authors:  D S Rao; J C Chang; P D Kumar; I Mizukami; G M Smithson; S V Bradley; A F Parlow; T S Ross
Journal:  Mol Cell Biol       Date:  2001-11       Impact factor: 4.272

6.  Aberrant Huntingtin interacting protein 1 in lymphoid malignancies.

Authors:  Sarah V Bradley; Mitchell R Smith; Teresa S Hyun; Peter C Lucas; Lina Li; Danielle Antonuk; Indira Joshi; Fang Jin; Theodora S Ross
Journal:  Cancer Res       Date:  2007-09-15       Impact factor: 12.701

7.  Role of the ENTH domain in phosphatidylinositol-4,5-bisphosphate binding and endocytosis.

Authors:  T Itoh; S Koshiba; T Kigawa; A Kikuchi; S Yokoyama; T Takenawa
Journal:  Science       Date:  2001-02-09       Impact factor: 47.728

8.  Simultaneous binding of PtdIns(4,5)P2 and clathrin by AP180 in the nucleation of clathrin lattices on membranes.

Authors:  M G Ford; B M Pearse; M K Higgins; Y Vallis; D J Owen; A Gibson; C R Hopkins; P R Evans; H T McMahon
Journal:  Science       Date:  2001-02-09       Impact factor: 47.728

9.  The actin-binding protein Hip1R associates with clathrin during early stages of endocytosis and promotes clathrin assembly in vitro.

Authors:  A E Engqvist-Goldstein; R A Warren; M M Kessels; J H Keen; J Heuser; D G Drubin
Journal:  J Cell Biol       Date:  2001-09-17       Impact factor: 10.539

10.  An actin-binding protein of the Sla2/Huntingtin interacting protein 1 family is a novel component of clathrin-coated pits and vesicles.

Authors:  A E Engqvist-Goldstein; M M Kessels; V S Chopra; M R Hayden; D G Drubin
Journal:  J Cell Biol       Date:  1999-12-27       Impact factor: 10.539

View more
  3 in total

1.  Huntingtin-interacting protein 1 phosphorylation by receptor tyrosine kinases.

Authors:  Heather M Ames; Anmin A Wang; Alanna Coughran; Kristen Evaul; Sha Huang; Chiron W Graves; Abigail A Soyombo; Theodora S Ross
Journal:  Mol Cell Biol       Date:  2013-07-08       Impact factor: 4.272

2.  Deficiency of the Endocytic Protein Hip1 Leads to Decreased Gdpd3 Expression, Low Phosphocholine, and Kypholordosis.

Authors:  Ranjula Wijayatunge; Sam R Holmstrom; Samantha B Foley; Victoria E Mgbemena; Varsha Bhargava; Gerardo Lopez Perez; Kelly McCrum; Theodora S Ross
Journal:  Mol Cell Biol       Date:  2018-11-13       Impact factor: 4.272

3.  Toward a therapeutic reduction of imatinib refractory myeloproliferative neoplasm-initiating cells.

Authors:  S T Philips; Z L Hildenbrand; K I Oravecz-Wilson; S B Foley; V E Mgbemena; T S Ross
Journal:  Oncogene       Date:  2013-11-18       Impact factor: 9.867

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.